Phase 2, open-label study of intratumoral tavokinogene telseplasmid (tavo) plus electroporation in combination with intravenous pembrolizumab therapy in patients with inoperable locally advanced or metastatic triple-negative breast cancer (mTNBC) (KEYNOTE-890/OMS-I141)-MedSci.cn

Phase 2, open-label study of intratumoral tavokinogene telseplasmid (tavo) plus electroporation in combination with intravenous pembrolizumab therapy in patients with inoperable locally advanced or metastatic triple-negative breast cancer (mTNBC) (KEYNOTE-890/OMS-I141)

Telli, ML; Wapnir, I; Devitt, B; Cuff, K; Soliman, H; Vinayak, S; Canton, DA; Twitty, C; Foerter, KM; Joshi, R

CANCER RESEARCH, 2020; 80 (4):

科室
- - 订阅+
  - 更多科室
工具
服务